Genmab at bank of america global healthcare conference: late-stage push

Genmab outlined three pivotal oncology readouts in Q4 2026 and Q1 2027—covering EPKINLY, Rina-S and petosemtamab—with all three assets potentially launching in 2027 if data and approvals are favorable. Petosemtamab is projected to exceed $1 billion in sales by 2029, while expanded Phase III programs in colorectal, head-and-neck, ovarian and endometrial cancers broaden the company’s growth runway beyond Darzalex royalty exposure. Management cautioned that consensus estimates understate increased R&D, SG&A and straight-line amortization of roughly DKK 7 billion for petosemtamab and more than DKK 1 billion for Rina-S, creating a material reported-earnings headwind after launch. Shares had risen 38% over six months to $34.96, near the $35.43 52-week high, leaving execution on upcoming clinical data as the key catalyst and risk.

Analysis

GMAB is transitioning from a royalty-supported earnings profile to a binary, capital-intensive oncology developer at precisely the point its valuation embeds unusually high confidence. The underappreciated issue is not simply higher operating expense: the acquired-asset amortization creates a visible gap between cash economics and reported EPS after launch, likely forcing 2027-28 consensus EPS cuts and limiting multiple expansion even if the pipeline delivers. Investors should value the company on risk-adjusted commercial cash flow and royalty durability, not a near-term P/E that will become less comparable as launch costs and amortization ramp.

The Q4 catalyst cluster is correlated rather than diversified: three positive outcomes would validate commercial-platform leverage, but one or more misses would expose how much of the current enterprise value is assigned to assets acquired at elevated prices. Petosemtamab's Q4 endpoint is an interim response-based readout rather than the more value-defining survival result due in Q1; a positive response result without compelling durability or subsequent OS would not settle competitive positioning against JNJ and BCAX. For Rina-S, a positive result could pressure ELHERE's franchise economics indirectly, but the ADC field is likely to compete on sequencing and tolerability rather than winner-take-all efficacy, tempering the implied downside for ABBV.

Contrarian view: the market may be too focused on first-in-class timing and too little on launch execution. Simultaneous 2027 launches could dilute sales-force attention, increase SG&A ahead of revenue, and make payer/formulary access the binding constraint; this is especially relevant where incumbent standards already shape physician behavior. Conversely, if EPKINLY's frontline result is clearly positive, it is the least appreciated near-term value unlock because it monetizes through an existing commercial partnership and can validate the company's ability to translate earlier-stage signals into registrational outcomes before wholly owned launches begin.

Key Decisions for Investors

• Maintain GMAB as a catalyst watch rather than add aggressively before Q4: initiate only after the ESMO colorectal dataset and ahead of Q4 if efficacy durability and safety support the Phase III expansion rationale. Use a 6-12 month horizon; thesis is falsified by a negative Rina-S Phase III result, an EPKINLY interim miss, or management guiding 2027 operating costs materially above revised consensus.
• For existing GMAB longs, reduce gross exposure into the tightly clustered Q4 readouts and retain upside via a defined-risk call spread extending through Q1 2027 rather than unhedged equity. The key risk/reward asymmetry is that Q4 petosemtamab data may be insufficient to prove the ultimate survival thesis, while the stock already prices substantial pipeline success.
• Monitor a relative-value basket long GMAB / short BCAX only after GMAB's Q1 2027 overall-survival readout, not before. The trade requires confirmation that petosemtamab has a clinically meaningful OS and tolerability advantage; absent that evidence, cross-trial comparisons are not investable and BCAX's lower expectations can outperform on merely acceptable data.
• Watch ABBV for an overreaction to Rina-S data: consider buying ABBV on a material drawdown following a positive GMAB readout if ELAHERE prescription persistence, FRalpha testing rates, and ovarian franchise guidance remain intact. A broader-label competitor is a medium-term risk, but near-term market-share displacement is constrained by treatment sequencing and adoption inertia.